Clinical trial
SPL7013 Gel - Male Tolerance Study
NCT00370357 · Starpharma Pty Ltd, Industry · Completed
Key facts
| NCT number | NCT00370357 |
|---|---|
| Title | SPL7013 Gel - Male Tolerance Study |
| Official title | A Phase 1, Placebo Controlled Study of the Safety of 3% w/w SPL7013 Gel, Administered to the Penis of Healthy Male Volunteers Once Daily for Seven Days |
| Lead sponsor | Starpharma Pty Ltd, Industry |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Human Immunodeficiency Virus (HIV) |
| Intervention type | Drug |
| Interventions | 3% w/w SPL7013 Gel (VivaGel™) |
| Enrollment | 36 |
| Start date | Aug 1, 2006 |
| Primary completion | Feb 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Aug 31, 2006 |
| Last update posted | Jan 16, 2008 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: